https://japsr.in/index.php/journal <p>Journal of Applied Pharmaceutical Sciences and Research (JAPSR) is a multi-disciplinary international, peer-reviewed, open access journal devoted to various segments of pharmaceutical and applied sciences. It’s a quarterly published journal that publishes quality manuscripts (original research, reviews, short communications, mini reviews, case studies and conference proceedings) relevant to the various fields of Pharmaceutical and Applied Sciences.</p> Journal of Applied Pharmaceutical Sciences and Research en-US Journal of Applied Pharmaceutical Sciences and Research 2581-5520 <p>All the articles published in JAPSR are distributed under a creative commons license (<a href="https://creativecommons.org/licenses/by-nc-sa/4.0/"><span class="tool-identifier">CC BY-NC-SA 4.0</span></a>)</p> <p><strong>Under this license, you are free to:</strong></p> <ul> <li class="show"><strong>Share</strong>- copy and redistribute the material in any medium or format for any purpose, even commercially.</li> <li class="show"><strong>Adapt</strong>- remix, transform, and build upon the material for any purpose, even commercially.</li> </ul> <p>The licensor cannot revoke these freedoms as long as you follow the license terms.</p> <ul> <li class="cc-by"><strong>Attribution&nbsp;</strong>— You must give&nbsp;<a id="src-appropriate-credit" href="https://creativecommons.org/licenses/by-nc-sa/4.0/#ref-appropriate-credit">appropriate credit&nbsp;</a>, provide a link to the license, and&nbsp;<a id="src-indicate-changes" href="https://creativecommons.org/licenses/by-nc-sa/4.0/#ref-indicate-changes">indicate if changes were made&nbsp;</a>. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</li> <li class="cc-nc"><strong>NonCommercial&nbsp;</strong>— You may not use the material for&nbsp;<a id="src-commercial-purposes" href="https://creativecommons.org/licenses/by-nc-sa/4.0/#ref-commercial-purposes">commercial purposes&nbsp;</a>.</li> <li class="cc-sa"><strong>ShareAlike&nbsp;</strong>— If you remix, transform, or build upon the material, you must distribute your contributions under the&nbsp;<a id="src-same-license" href="https://creativecommons.org/licenses/by-nc-sa/4.0/#ref-same-license">same license&nbsp;</a>as the original.</li> <li><strong>No additional restrictions&nbsp;</strong>— You may not apply legal terms or&nbsp;<a id="src-technological-measures" href="https://creativecommons.org/licenses/by-nc-sa/4.0/#ref-technological-measures">technological measures&nbsp;</a>that legally restrict others from doing anything the license permits.</li> </ul> <p><strong>Copyright policy</strong></p> <p>The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.</p> <p><strong>Licensing policy</strong></p> <p>The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.</p> https://japsr.in/index.php/journal/article/view/379 <p>Objective: The current study objective was to develop and validate a simple, rapid, and stability-indicating RP-HPLC method for the&nbsp;quantitative determination of tegoprazan in bulk drug and pharmaceutical formulations.<br>Materials &amp; Methods: The chromatographic separation was achieved on Waters XBridge C18 column (250 × 4.6 mm, 5 μm) using acetonitrile and 0.02 M potassium dihydrogen phosphate buffer (60:40, v/v) adjusted to pH 5.2 at 1.0 mL/min as mobile phase. Detection was carried out at 303 nm with a total run time of 6 min. In the optimized conditions, tegoprazan display sharp and symmetrical peak at a retention time of approximately 2.5 min.<br>Results: The developed method produces excellent linearity over 10–60 μg/mL with a regression coefficient (R²) of 0.9994. The limits of detection (LOD) and quantification (LOQ) were noticed to be 0.03 μg/mL and 0.10 μg/mL, respectively indicates high sensitivity of the method. Precision studies produce %RSD values of &lt;2%, proves good repeatability and intermediate precision. Accuracy assessed by recovery studies at 50%, 100%, and 150% levels yields recoveries between 98.30% and 101.11%. Robustness evaluation demonstrates minimal variation (&lt;2%) upon small deliberate changes in chromatographic parameters. The forced degradation studies reveal that tegoprazan was most susceptible to acidic conditions and display good stability under oxidative, thermal, and photolytic stress. The method was successfully applied to the analysis of a commercial formulation with an assay value of 99.52%.<br>Conclusion: The developed method was simple, accurate, precise, and stability-indicating and suitable for routine quality control as&nbsp;well as stability analysis of tegoprazan in bulk drug and pharmaceutical dosage forms.</p> Raghavendra Kumar Gunda Sai Prudhvi N Lakshmi Swarupa Ch Soumya M Bhavya Sri J Anjali K Kousar Begum Sk ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc-sa/4.0/ 2026-06-03 2026-06-03 9 02 1 8 10.31069/japsr.v9i2.01 https://japsr.in/index.php/journal/article/view/381 <p>Objective: The current study was to develop a simple, rapid, and reliable RP-HPLC method was proposed for the quantification of Upadacitinib in bulk drug and pharmaceutical dosage forms.<br>Materials &amp; Methods: Separation was achieved on C18 column using ethanol and 10 mM ammonium acetate in 60:40 (v/v) at isocratic flow rate of 0.5 mL/min over 6 min runtime. The method produces sharp and well-resolved peak with 2.8 min retention time. It displays excellent specificity, with no interference from excipients.<br>Results: System suitability results were within acceptable limits, with tailing factor of 1.03 and 5813 theoretical plates indicates good column efficiency. The method demonstrates high sensitivity, with LOD and LOQ values of 0.025 μg/mL and 0.082 μg/mL, respectively. A strong linear response was noticed over 30-105 μg/mL (r² = 0.9999). Precision was proved with %RSD values of 0.49 (intra-day) and 0.60 (inter-day), while accuracy was observed in the range of 99.38 % to 100.47%. The method remains stable under small deliberate variations proves its robustness and ruggedness. The forced degradation studies show highest degradation under peroxide (8.76%), and acidic (4.75%), while drug remains stable under basic (3.81%) conditions, thermal (5.07%) and photolytic (2.12%) stress. No interference from degradation products was observed proves its stability-indicating capability. The assay was noticed to be 99.12 % and demonstrates suitability for routine quality and stability assessment of Upadacitinib. The sustainability of the method was evaluated with the use of<br>the AGREE (0.82), and GAPI (4.8E+02), displayed in the center corresponds to the E-factor of 475, meaning that approximately 475 g of waste is generated per gram of analyte analyzed.<br>Conclusion: Overall, the results demonstrate the ability of the method to maintain a good balance between analysis reliability, environmental effects, and operational convenience.</p> Sai Prudhvi N Raghavendra Kumar Gunda Lakshmi Swarupa Ch Rani R Akhila T Meghana K Sharon P Venkata Sri Kavya S ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc-sa/4.0/ 2026-06-03 2026-06-03 9 02 9 18 10.31069/japsr.v9i2.02